[Impact of molecular targeting therapy on tumor immunity]

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Oncogenic pathways are central to molecularly targeted therapies.
• These pathways significantly influence the tumor microenvironment's immunosuppressive nature.
• Key pathways like EGFR, BRAF, PI3K, and JAK-Stat3 activation contribute to immune evasion.

Purpose of the Study:

• To elucidate the mechanisms linking molecularly targetable oncogenes to immunosuppressive tumor microenvironments.
• To explore how these oncogenes modulate immune responses within the tumor.
• To identify strategies for combining molecular targeting with immunotherapies.

Main Methods:

• Review of emerging evidence on oncogenic pathways and tumor microenvironment interactions.
• Analysis of immune modulatory pathway activation (e.g., PD-L1 upregulation, PI3K, JAK-Stat3).
• Focus on genetic mutations (EGFR, BRAF) and their role in immune modulation.

Main Results:

• Oncogenic pathways are critical in establishing immunosuppressive tumor microenvironments.
• Activation of pathways like PI3K and JAK-Stat3, and mutations in EGFR/BRAF, can upregulate PD-L1.
• These molecular alterations significantly impact tumor immunosurveillance quality.

Conclusions:

• Targeting oncogenic pathways can influence tumor immune responses.
• Understanding these interactions is crucial for developing effective combination strategies.
• Combining molecular targeting and immunotherapies holds promise for future cancer treatment.